知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

72 条记录 (耗时 0.05 秒)

    Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
    1.
    发明授权
    Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 有权
    片剂形状以增强可膨胀控释口服剂型的胃滞留

    公开(公告)号：US06488962B1

    公开(公告)日：2002-12-03

    申请号：US09598061

    申请日：2000-06-20

    申请人： Bret Berner ,  Jenny Louie-Helm

    发明人： Bret Berner ,  Jenny Louie-Helm

    IPC分类号： A61K914

    CPC分类号： A61K9/0065 ,  A61K9/2031 ,  A61K9/2072

    摘要： The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.

    摘要翻译： 口服药物剂型在胃中的保留通过使用可膨胀的剂型来改善，其可以以防止它们因特定方向而无意地穿过幽门的方式成型。 形状的平面突起是具有不同长度的两个正交轴的平面突起，其长度足够短以允许在肿胀之前容易吞咽，而较短的时间足以在半小时内膨胀以防止通过幽门。

    Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
    5.
    发明授权
    Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract 有权
    在胃肠道下部限制药物释放的胃保持性口服剂型

    公开(公告)号：US07976870B2

    公开(公告)日：2011-07-12

    申请号：US10769574

    申请日：2004-01-29

    申请人： Bret Berner ,  Jenny Louie-Helm ,  John W. Shell

    发明人： Bret Berner ,  Jenny Louie-Helm ,  John W. Shell

    IPC分类号： A61K9/22 ,  A61K9/20 ,  A61K9/32

    CPC分类号： A61K9/0065 ,  A61K9/20 ,  A61K9/2031 ,  A61K31/00 ,  A61K31/195 ,  A61K31/197 ,  A61K31/496 ,  A61K31/65 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481

    摘要： Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.

    摘要翻译： 提供了控制释放的口服剂型，用于将药理学活性剂连续，持续给药至患有进食模式的患者的上消化道。 大多数药剂在延长释放的基础上被递送到小肠的胃，十二指肠和上部区域，药物在下胃肠道和结肠中的输送受到限制。 所述剂型包含生物相容的亲水性可侵蚀聚合物与其中掺入活性剂的基质，其中所述聚合物是在水存在下溶胀并在数小时内逐渐侵蚀的聚合物，其起始于膨胀和侵蚀 接触胃液，药物释放率主要受侵蚀速度控制。

    Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
    9.
    发明授权
    Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 有权
    胃酸滞留剂用于将阿坎酸延长释放到上消化道

    公开(公告)号：US09000046B2

    公开(公告)日：2015-04-07

    申请号：US13247956

    申请日：2011-09-28

    申请人： Bret Berner ,  Cuiping Chen

    发明人： Bret Berner ,  Cuiping Chen

    IPC分类号： A61K31/16 ,  A61K9/22 ,  A61K9/26 ,  A61K31/185 ,  A61K9/00 ,  A61K9/20

    CPC分类号： A61K9/0065 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/185 ,  A61K47/10

    摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

    摘要翻译： 描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次 疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。 还描述了使用剂型和制备剂型的方法的治疗方法。

    GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT
    10.
    发明申请
    GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT 有权
    胃肠增强剂用于延长胃肠激素释放的胃肠道剂量

    公开(公告)号：US20120077878A1

    公开(公告)日：2012-03-29

    申请号：US13247956

    申请日：2011-09-28

    申请人： Bret Berner ,  Cuiping Chen

    发明人： Bret Berner ,  Cuiping Chen

    IPC分类号： A61K31/185 ,  A61P25/32

    CPC分类号： A61K9/0065 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/185 ,  A61K47/10

    摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

    摘要翻译： 描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次 疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。 还描述了使用剂型和制备剂型的方法的治疗方法。